Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer.

ABSTRACT:

Introduction

A significant proportion of patients with metastatic castration-resistant prostate cancer (mCRPC) harbor mutations in homologous recombination (HR) repair genes, with some of these mutations associating with increased tumor susceptibility to poly(ADP-ribose) polymerase (PARP) inhibitors and platinum-based chemotherapy. While mutations in some HR repair genes (e.g., BRCA1/2) have been associated with a more aggressive clinical course, prior studies correlating HR mutational status with treatment response to androgen receptor (AR) signaling inhibitors (ARSIs) or taxane-based chemotherapy have yielded conflicting results.

Methods

We conducted a single-center retrospective analysis to assess clinical outcomes to conventional, regulatory-approved therapies in mCRPC p

SUBMITTER: Carlson AS 

PROVIDER: S-EPMC7526881 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature